Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, weighs in on additional data from the phase III COMMANDS trial presented by Matteo Giovanni Della Porta, MD, during the 2023 European Hematology Association (EHA) Congress.
Dr. Garcia-Manero presented results from the phase III COMMANDS trial during the 2023 American Society of Clinical Oncology Annual Meeting.
The data presented at the 2023 EHA Congress adds to those results by showing patients with myelodysplastic syndromes (MDS) who received luspatercept-aamt had a “higher probability of achieving clinical benefit, regardless of overall mutational burden,” officials said in a news release.
The open-label, randomized trial evaluated luspatercept-aamt versus epoetin alfa for the treatment of anemia in adults with very low-, low- or intermediate-risk MDS. All patients in the study required red blood cell transfusions and had not previously received an erythropoietin stimulating agent.